Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

Share Price is delayed by 15 minutes
Get Live Data
0.60    -0.04 (-6.25%)
Bid:
0.502
Ask:
0.598
Spread: 0.096 (19.124%)
Market Cap: £3.49m
FUM Live PriceLast checked at - London Stock Exchange

Intraday Futura Medical Share Chart

Directorate Changes

20 Feb 2018 07:00

RNS Number : 3598F
Futura Medical PLC
20 February 2018
 

For immediate release

20 February 2018

 

 

 

 

 

Futura Medical plc

("Futura" or "the Company")

 

Directorate Changes

 

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, announces that Derek Martin, the Company's Finance Director, has resigned from the Board and will leave the Company with effect from the date of this announcement to pursue other business interests.

 

Angela Hildreth will join the Company in the role of Finance Director, Chief Operating Officer and Board Director with effect from the date of this announcement. Angela is an experienced executive with a track record gained in financial, operational and strategic roles in healthcare and other industries. Angela's experience includes the AIM market and development-stage companies.

 

Angela was most recently the UK finance director of Shield Therapeutics plc, having joined the business as its financial controller in 2011 when it was an unquoted start-up. Her breadth of roles at the business included finance, business development, human resources and IT.

 

James Barder, Futura's Chief Executive, said: "On behalf of the Board, I would like to thank Derek for his contribution to the development of the Company during almost 10 years as Finance Director having been appointed on 24 September 2008. We wish him all the best in his future activities.

 

"I am delighted to welcome Angela to the role of FD and COO at Futura. Her breadth of knowledge and commercial experience in the pharmaceutical sector will be of great value to the Company at a key stage in our development."

 

 

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Angela Hildreth (née Bowman), aged 38 years, has been a director of the following companies during the five years preceding the date of this announcement:

 

Current directorships Past directorships

Quaff Box Limited Shield Therapeutics Switzerland AG

Shield TX UK Limited

Phosphate Therapeutics Limited

 

There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

 

 

For any further information please contact:

 

 

Futura Medical plc

 

James Barder, Chief Executive

 

Tel: +44 (0)1483 685 670

mail to: james.barder@futuramedical.com

www.futuramedical.com

 

 

 

N+1 Singer (Nominated Adviser and Broker)

 

Aubrey Powell / Liz Yong

 

Tel:+44 (0) 20 7496 3000

 

 

For media enquiries please contact:

 

 

Buchanan

 

Mark Court / Sophie Wills / Stephanie Watson

Tel: +44 (0)20 7466 5000

 

 

 

Notes to Editors

 

Futura Medical plc

 

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

 

www.futuramedical.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAMMGZZVGFGRZG
Date   Source Headline
30th Mar 20212:18 pmRNSNotice of Results
25th Mar 20214:41 pmRNSSecond Price Monitoring Extn
25th Mar 20214:36 pmRNSPrice Monitoring Extension
24th Mar 202111:05 amRNSSecond Price Monitoring Extn
24th Mar 202111:00 amRNSPrice Monitoring Extension
24th Mar 20219:05 amRNSSecond Price Monitoring Extn
24th Mar 20219:00 amRNSPrice Monitoring Extension
23rd Mar 20214:41 pmRNSSecond Price Monitoring Extn
23rd Mar 20214:36 pmRNSPrice Monitoring Extension
23rd Mar 20212:05 pmRNSSecond Price Monitoring Extn
23rd Mar 20212:01 pmRNSPrice Monitoring Extension
23rd Mar 20219:05 amRNSSecond Price Monitoring Extn
23rd Mar 20219:00 amRNSPrice Monitoring Extension
22nd Mar 20217:00 amRNSUS FDA Agreement for Confirmatory Clinical study
19th Mar 20214:41 pmRNSSecond Price Monitoring Extn
19th Mar 20214:36 pmRNSPrice Monitoring Extension
19th Mar 202111:06 amRNSSecond Price Monitoring Extn
19th Mar 202111:00 amRNSPrice Monitoring Extension
19th Mar 20217:00 amRNSFutura Receives Recommendation for Approval
4th Mar 20212:05 pmRNSSecond Price Monitoring Extn
4th Mar 20212:00 pmRNSPrice Monitoring Extension
4th Mar 20219:06 amRNSSecond Price Monitoring Extn
4th Mar 20219:00 amRNSPrice Monitoring Extension
4th Mar 20217:00 amRNSFutura Announces Investment & Joint Collaboration
25th Feb 20212:06 pmRNSSecond Price Monitoring Extn
25th Feb 20212:01 pmRNSPrice Monitoring Extension
22nd Feb 20214:41 pmRNSSecond Price Monitoring Extn
22nd Feb 20214:36 pmRNSPrice Monitoring Extension
22nd Feb 20212:05 pmRNSSecond Price Monitoring Extn
22nd Feb 20212:00 pmRNSPrice Monitoring Extension
18th Feb 202111:06 amRNSSecond Price Monitoring Extn
18th Feb 202111:00 amRNSPrice Monitoring Extension
15th Dec 20202:00 pmRNSPrice Monitoring Extension
15th Dec 20209:05 amRNSSecond Price Monitoring Extn
15th Dec 20209:00 amRNSPrice Monitoring Extension
8th Dec 20207:00 amRNSFutura provides US regulatory & commercial update
1st Dec 20207:00 amRNSBlock Listing Six Monthly Return
22nd Oct 20207:00 amRNSFutura provides regulatory and commercial update
21st Sep 20203:12 pmRNSDirector/PDMR Shareholding
16th Sep 20207:00 amRNSInterim Results for Six Months ended 30 June 2020
10th Sep 20204:41 pmRNSSecond Price Monitoring Extn
10th Sep 20204:35 pmRNSPrice Monitoring Extension
17th Aug 20207:00 amRNSNotice of Results
10th Aug 20207:00 amRNSFutura receives positive QMS Audit Opinion
4th Aug 20207:00 amRNSFutura update on CBD100 1st Stage Development Work
24th Jul 20204:40 pmRNSSecond Price Monitoring Extn
24th Jul 20204:35 pmRNSPrice Monitoring Extension
14th Jul 20207:00 amRNSFutura Medical provides EU & US regulatory update
10th Jul 20204:31 pmRNSBlock listing Interim Review - Replacement
24th Jun 20204:22 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.